{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:11:01Z","timestamp":1791616261706,"version":"4.3.4"},"reference-count":18,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100024516","name":"Astellas Pharma Deutschland","doi-asserted-by":"publisher","award":["EV\u2010000019810"],"award-info":[{"award-number":["EV\u2010000019810"]}],"id":[{"id":"10.13039\/501100024516","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2026,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Antibody\u2010drug conjugates (ADCs) and immunotherapy have changed the treatment landscape for locally advanced and metastatic urothelial carcinoma (la\/mUC). Clinical trials have demonstrated the superiority of enfortumab vedotin (EV) combined with pembrolizumab (P) over chemotherapy. This retrospective, multicentre Austrian registry analysis evaluated the effectiveness and safety of EV\u2009+\u2009P in treatment\u2010na\u00efve la\/mUC patients in a real\u2010world setting. This study included 203 first\u2010line EV\u2009+\u2009P treated patients from 20 Austrian centres. The majority were male (77.3%), with a median age of 70\u2009years (range, 26\u201392), while 33.5% were \u226575\u2009years. Comorbidities were common, with 25.1% having a Charlson Comorbidity Index (CCI) \u2265\u20095, and 46.3% moderate to severe renal impairment. Among 195 evaluable patients, the objective response rate (ORR) was 63.6% (95% CI, 56.6\u201370.0), including 21.5% complete responses and 42.1% partial responses. Disease control was achieved in 75.4% (95% CI, 68.9\u201380.9). Median progression\u2010free survival (PFS) and overall survival (OS) were not reached after a median follow\u2010up of 5.8\u2009months. Poor outcomes were associated with ECOG PS &gt;2 (PFS,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009.003; OS,\n                    <jats:italic>p<\/jats:italic>\n                    &lt; .001) and CCI \u22655 (PFS,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009.011; OS,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009.08). EV\u2009+\u2009P was generally well tolerated; grade \u22653 treatment\u2010related adverse events occurred in 38.4% of patients and immune\u2010related adverse events in 19.2%. Limitations of this study include its retrospective design and short follow\u2010up. These findings support the clinical use of EV\u2009+\u2009P as first\u2010line treatment for la\/mUC, demonstrating substantial effectiveness and manageable toxicity in a large real\u2010world population, including elderly and comorbid patients. Extended follow\u2010up is warranted to determine long\u2010term survival and predictive markers of response.\n                  <\/jats:p>","DOI":"10.1002\/ijc.70203","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:25:26Z","timestamp":1761128726000},"page":"1654-1665","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enfortumab vedotin plus pembrolizumab in treatment\u2010na\u00efve metastatic urothelial carcinoma patients: An Austrian real\u2010world analysis"],"prefix":"10.1002","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0544-5773","authenticated-orcid":false,"given":"Dora","family":"Niedersuess\u2010Beke","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I., Centre for Oncology and Haematology Vienna Healthcare Group  Ottakring Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Mayrhofer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I., Centre for Oncology and Haematology Vienna Healthcare Group  Ottakring Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Krauter","sequence":"additional","affiliation":[{"name":"Department of Urology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Franke","sequence":"additional","affiliation":[{"name":"Department of Urology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Vais","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Oncology and Haematology State Hospital Klagenfurt  Klagenfurt Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximillian","family":"Pallauf","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Salzburg Paracelsus Medical University Salzburg  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kiesl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I with Haematology, Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz Austria and Johannes Kepler University  Linz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"Luger","sequence":"additional","affiliation":[{"name":"Department of Urology Ordensklinikum Linz Elisabethinen  Linz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Pfuner","sequence":"additional","affiliation":[{"name":"Department of Urology Klinikum Donaustadt  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Terbuch","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology, Department of Internal Medicine Medical University Graz  Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bauernhofer","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology, Department of Internal Medicine Medical University Graz  Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Spielgelberg","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Palliative Medicine Klinikum Oberwart  Oberwart Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Banner","sequence":"additional","affiliation":[{"name":"Department of Urology Vienna Healthcare Group, Favoriten  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Aufderklamm","sequence":"additional","affiliation":[{"name":"Department of Urology State Hospital Bregenz  Bregenz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Wiesinger","sequence":"additional","affiliation":[{"name":"Department of Urology Klinikum Wels\u2010Grieskirchen  Wels Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schnabel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Centre Paracelsus Medical University Salzburg  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3966-1071","authenticated-orcid":false,"given":"Simon Peter","family":"Gampenrieder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Centre Paracelsus Medical University Salzburg  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"M\u00fchlmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine St. John of God Hospital  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Vallet","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II University Hospital Krems and Karl Landsteiner University of Health Sciences  Krems an der Donau Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Weibrecht","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II St. John of God Hospital  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Stoiber","sequence":"additional","affiliation":[{"name":"Department of Urology State Hospital Salzkammergut  V\u00f6cklabruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Andalibi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Oncology and Haematology Barmherzige Schwestern  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harun","family":"Fajkovic","sequence":"additional","affiliation":[{"name":"Department of Urology and Andrology University Hospital St. P\u00f6lten  St. P\u00f6lten Austria"},{"name":"Department for Urology Karl Landsteiner Institute for Urological Research and Training  St. P\u00f6lten Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Taghizadeh","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospital St. P\u00f6lten  St. P\u00f6lten Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Miechowiecki","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology Hanusch Krankenhaus of the OEGK, Hanusch Hospital  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Taedcke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I., Centre for Oncology and Haematology Vienna Healthcare Group  Ottakring Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Heintel","sequence":"additional","affiliation":[{"name":"Department for Oncology Karl Landsteiner Institute for Bioanalytical Oncology  Horn Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[{"name":"Department of Urology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pichler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Oncology and Haematology Klinik Oberwart  Oberwart Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hilbe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I., Centre for Oncology and Haematology Vienna Healthcare Group  Ottakring Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5286-9048","authenticated-orcid":false,"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[{"name":"Department of Urology, Comprehensive Cancer Centre Innsbruck Medical University of Innsbruck  Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_14_3_1","volume-title":"StatPearls Publishing Copyright 2024","author":"Kaseb H","year":"2024"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100599"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211047352"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_2_14_9_1","unstructured":"Enfortumab vedotin (PADCEV) prescribing information.2025Last accessed on September 4 2025 from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761137s000lbl.pdf"},{"key":"e_1_2_14_10_1","unstructured":"SmPC Enfortumab Vedotin (PADCEV).Last accessed on September 4 2025.2025from:https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/padcev-epar-product-information_en.pdf"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102278"},{"issue":"5","key":"e_1_2_14_13_1","article-title":"EV\u2010302: updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolozumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la\/mUC)","volume":"43","author":"Powles T","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"e_1_2_14_14_1","article-title":"Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (La\/mUC): subgroup analyses from EV\u2010302, a phase 3 global study","volume":"42","author":"Heijden MS","year":"2024","journal-title":"J Clin Oncol"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2073"},{"issue":"5","key":"e_1_2_14_16_1","article-title":"Clinical efficacy of enfortumab vedotin\u2010pembrolizumab (EV\u2010Pembro) in locally\u2010advanced (LA) or metastatic urothelial carcinoma (mUC): a real\u2010world retrospective study","volume":"43","author":"Jain P","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_2_14_17_1","article-title":"Enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma: first results on outcomes and safety in a German multicenter real\u2010world patient cohort (guardians)","volume":"43","author":"Zschaebitz S","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_2_14_18_1","article-title":"Enfortumab vedotin\u2010related skin toxicities in patients with urthelial carcinoma: a systematic review and meta\u2010analysis","volume":"43","author":"Gazzoni G","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_2_14_19_1","article-title":"Real\u2010world time on treatment with first\u2010line enfortumab vedotin plus pembrolizumab after US food and drug administration approval for advanced urothelial cancer","volume":"43","author":"Mayer MN","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.70203","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:23:07Z","timestamp":1787761387000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,15]]}},"alternative-id":["10.1002\/ijc.70203"],"URL":"https:\/\/doi.org\/10.1002\/ijc.70203","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"2025-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}